Related Experiment Video

Updated: Jul 13, 2026

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional

Jing Deng1, Nicole Carlson, Kunihiko Takeyama

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

Cancer Cell
|August 19, 2007
PubMed

Insights

BH3 profiling identifies cancer cell apoptosis defects, classifying them by pathway position. This method predicts sensitivity to targeted therapies like ABT-737 and conventional chemotherapy, aiding rational cancer treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Cancer cells often evade apoptosis, a programmed cell death process, through various mechanisms.
  • Understanding and targeting these apoptotic blocks is crucial for developing effective cancer therapies.

Purpose of the Study:

  • To develop and validate BH3 profiling as a method to identify cancer-specific apoptotic defects.
  • To classify cancer cells based on their apoptotic pathway vulnerabilities.
  • To correlate these defects with sensitivity to specific anti-cancer agents.

Main Methods:

  • BH3 profiling was applied to a panel of 18 lymphoma cell lines.
  • Analysis focused on identifying dependencies on anti-apoptotic proteins like BCL-2.
  • Correlation of BH3 profiling results with sensitivity to ABT-737 and conventional chemotherapeutics.

Main Results:

  • BH3 profiling successfully identified apoptotic defects and classified cells into three distinct groups.
  • The method predicted BCL-2 dependence, which correlated with BIM sequestration.
  • BH3 profiling accurately predicted sensitivity to the BCL-2 inhibitor ABT-737.
  • Sensitivity to etoposide, vincristine, and adriamycin was also predicted by BH3 profiling.

Conclusions:

  • BH3 profiling is a valuable tool for dissecting apoptotic defects in cancer cells.
  • This technique can guide the rational selection of targeted therapies and conventional chemotherapy.
  • BH3 profiling offers a predictive biomarker for patient response to specific anti-cancer treatments.

More Related Videos

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...